Pharming Group N.V. Fourth quarter and full year 2025 financial results March 12, 2026 NASDAQ: PHAR | EURONEXT Amsterdam: PHARM CEO Fabrice Chouraqui Chief Executive Officer Introduction SPEAKERS Fabrice Chouraqui Chief Executive Officer Leverne Marsh Chief Commercial Officer Anurag Relan, MD Chief Medical Officer Kenneth Lynard Chief Financial Officer Forward-looking statements This presentation may contain forward-looking statements. Forward-looking statements are statements of future expectations that ar ...

Financial Data and Key Metrics Changes - For the quarter ending December 31, 2025, the company generated distributable earnings of $0.27 per share, impacted by a loan foreclosure which reduced earnings by approximately $0.03 per share [8][16] - For the full year ended December 31, 2025, net interest income was $21.6 million, with distributable earnings of $15.2 million or $1.19 per share [16] - The company ended the fourth quarter with total assets of $310.2 million and total shareholder equity of $182 million, with a book value of $13.56 per share [18] Business Line Data and Key Metrics Changes - The company closed on $368 million of loans during the fiscal year, with $247 million committed and $224 million funded by the company [7] - In the fourth quarter of 2025, the company closed on $56 million of commitments, including loans for industrial and retail properties [12] - As of February 27, 2026, the portfolio, excluding the Thompson Hotels, consisted of $442.1 million of current commitments and $337 million of principal outstanding across 16 loans [17] Market Data and Key Metrics Changes - The company observed a bifurcation in the commercial real estate lending market, with lenders focused on multifamily and industrial assets experiencing tight spreads [10] - The company noted that the market volatility has created opportunities for transitional deals, despite recent uncertainty due to rising rates [21][23] Company Strategy and Development Direction - The company remains focused on providing loans for transitional real estate business plans, primarily in the Southern United States, with a strategy centered on residential loans [5] - The company aims to partner with top-tier sponsors for high-quality real estate projects, emphasizing structured solutions for complex deals [11][13] Management's Comments on Operating Environment and Future Outlook - Management indicated that the current market volatility presents both challenges and opportunities, particularly in identifying transitional deals [21][23] - The company expressed confidence in its ability to capitalize on attractive opportunities despite the uncertain macroeconomic environment [46][47] Other Important Information - The board of directors declared a $0.30 dividend per share for the quarter ended March 31, 2026, which is expected to be covered over the next 6-12 months [8][32] - The company increased its revolving credit facility to $165 million, with potential to expand to $200 million [9] Q&A Session Summary Question: Market dynamics and investment opportunities - The company noted that market volatility has created a gap in transitional deals, providing opportunities despite uncertainty [21][23] Question: Loan pipeline reduction - Management confirmed that the loan pipeline decreased to $652 million due to a focus on high-quality, actionable deals amidst market volatility [27][28] Question: Foreclosure of the San Antonio asset - The company explained that the Thompson Hotel foreclosure was due to management issues and cash flow constraints, despite the asset being high-quality [29][30] Question: Dividend coverage expectations - Management stated that the board is confident in covering the dividend over the next 6-12 months [32] Question: Capital deployment trends - Management reflected on the evolving opportunity set and the need for selective capital deployment in light of market conditions [44][46]

Financial Data and Key Metrics Changes - Consolidated net revenue for Q4 2025 was approximately $97.8 million, down 16.5% year-over-year [9] - Adjusted EBITDA for the fourth quarter was $15.6 million, a decrease of 41.8% [15] - Net loss for Q4 2025 was approximately $54.4 million or $12.24 per share, compared to a net loss of $35.7 million or $7.81 per share for Q4 2024 [21][22] Business Line Data and Key Metrics Changes - Net revenue for the radio broadcasting segment was $35.1 million, a decrease of 26.5% year-over-year [9] - Reach Media segment net revenue was $13.8 million, up 43.9% from the prior year, primarily due to event revenue from the Fantastic Voyage cruise [11] - Digital segment net revenue was down 19.6% to $14.7 million, driven by decreased direct revenue streams [12] - Cable television segment revenue was approximately $34.9 million, a decrease of 16.8%, with advertising revenue down 21.8% [12] Market Data and Key Metrics Changes - Local ad sales were down 19% against markets that were down 12.6%, while national ad sales were down 40.1% against a market decline of 29.2% [9] - Cable subscribers for TV One decreased to 30.2 million from 34.1 million at the end of Q3 [12] Company Strategy and Development Direction - The company is focused on deleveraging its business and taking advantage of offensive opportunities, particularly in the deregulated radio business [6][7] - A significant capital markets transaction was completed, repurchasing a substantial amount of 2028 notes at a discount and extending maturities to 2031 [6][16] Management's Comments on Operating Environment and Future Outlook - The first quarter of 2026 started slower than expected, with current radio pacings down about 5% [5] - Management remains positive about operational changes and upcoming political events that may impact revenue [5] Other Important Information - The company completed a reverse stock split of 1-for-10 in January 2026 to regain compliance with Nasdaq listing requirements [22] - Capital expenditures for the quarter were approximately $3.2 million and $10.1 million for the year [21] Q&A Session Summary - There were no questions during the Q&A session [23]

Financial Data and Key Metrics Changes - In Q4 2025, the company generated net revenues of $6.6 million and EBITDA of $1.5 million, reflecting a decline compared to the same period last year due to a reduction in fleet and softer market conditions [3][12] - For the full year 2025, net revenue totaled $37.8 million, adjusted EBITDA was $12.9 million, and the net loss reached $6.2 million [12] - Daily operating expenses were successfully reduced to approximately $6,300 per day [13] Business Line Data and Key Metrics Changes - The company executed strategic initiatives to enhance earnings, including divesting lower-returning assets and redeploying proceeds into higher-earning Capesize exposure [4] - The fleet utilization remained high at 97.6%, and the fourth quarter TCE was $14,129, consistent with the same period in 2024 [6] Market Data and Key Metrics Changes - The Baltic Kamsarmax Index averaged about $14,800 in early 2026, up from $9,600 during the same period in 2025, while the Baltic Capesize Index averaged about $23,000, compared to $13,000 for the same period last year [8] - The Panamax market showed strong growth in grain and minor bulk ton-miles, while coal trade has moderated [9] Company Strategy and Development Direction - The company aims to transform into a strong cash flow engine, with a disciplined capital allocation approach and a focus on profitable investments [18][19] - The strategy includes acquiring Capesize vessels under profitable time charters and maintaining a balanced commercial strategy between index-linked exposure and fixed rates [7][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining competitive distributions while pursuing growth opportunities, citing strong fundamentals in the Panamax market and improved market conditions [4][7] - The geopolitical crisis in the Middle East adds uncertainty, but management expects increased coal trade flows to offset reduced cargo demand from the Arabian Gulf [9][25] Other Important Information - The company declared its thirteenth consecutive quarterly dividend, reflecting a commitment to capital returns, with cumulative cash dividends of approximately $1.84 per share since the program's initiation [3][18] - The company has engaged in extensive share repurchases as part of its capital returns options [18] Q&A Session Summary Question: Dividend policy and future payouts - Management intends to establish a clear formula for dividends, emphasizing a commitment to generous shareholder returns [21][22] Question: Acquisition details of the Squireship - The fixed rate for the Squireship is approximately $28,000, with a strategy to finance the acquisition at a leverage ratio of around 60%-65% [23] Question: Implications of coal trade flows - Management expects increased coal trades due to disruptions in LNG trade, particularly in the context of rising electrification needs [24][25] Question: Fleet presence in the Gulf area - Management noted that about 2% of the global fleet is in the Gulf area, which could impact market dynamics [26]

Financial Data and Key Metrics Changes - SNDL achieved record full-year net revenue of CAD 946 million, representing a growth of 2.8% year-over-year, supported by 11% growth from combined cannabis segments, partially offset by a 2.8% decline in liquor [10] - Free cash flow for 2025 reached CAD 18 million, more than doubling the result from the previous year [3][11] - Gross profit for Q4 was CAD 70.2 million, marking a new quarterly record, with a gross margin increase of 110 basis points to 27.8% [9] Business Line Data and Key Metrics Changes - The cannabis retail segment achieved a full-year revenue record of CAD 330 million, representing a 6% growth, supported by same-store sales growth of 3.9% and new store openings [19] - The liquor segment experienced a 2% year-over-year decline in net revenue for Q4, but managed to maintain or expand gross profit through productivity improvements [13][17] - Cannabis operations delivered record net revenue of CAD 144.7 million for the full year, representing a growth of 32%, supported by the Indiva acquisition [20] Market Data and Key Metrics Changes - Both retail and operations segments gained market share despite a market slowdown in the second half of 2025 [4] - The liquor segment faced a consistent revenue decline of approximately 3% year-over-year, driven by broader market conditions [17][43] - The cannabis market experienced a slowdown in the second half of 2025, leading to a decline in the fourth quarter [12][30] Company Strategy and Development Direction - SNDL is focused on growth, profitability, and people, with plans to continue expanding its market share through new store openings and strategic acquisitions [22][24] - The company aims to leverage its strong balance sheet with no debt and over CAD 250 million in unrestricted cash for disciplined capital deployment [5] - SNDL is positioned to capitalize on industry consolidation opportunities as less efficient operators face increased pressure [12][34] Management's Comments on Operating Environment and Future Outlook - Management noted that the market is becoming saturated, particularly in retail, leading to declines in traffic and top-line revenue [30] - The company remains committed to sustaining its upward trajectory in profitability despite market headwinds [12] - Management expressed optimism about the potential for international growth and the completion of EU GMP certification by summer [39] Other Important Information - SNDL has repurchased a total of 15.1 million shares since Q4 2024, including 4.3 million shares in the last 90 days [7] - The company is finalizing the acquisition of Cost Cannabis retail stores, incorporating five locations in Alberta and Saskatchewan [5][32] Q&A Session Summary Question: What is behind the slowdown in the SNDL retail segment? - Management attributed the slowdown to market saturation, competitive pressures, and a shift in focus towards profitability and mix improvements [30] Question: When is the acquisition of 1CM Inc. stores expected to close? - Management expects to report back to shareholders on the timing in Q2, as they are finalizing their review with the AGCO [33] Question: How does SNDL view the liquor retail market outlook for 2026? - Management indicated that while there are structural challenges, certain areas within their portfolio, like the Wine and Beyond banner, are showing strength and growth [44] Question: What is the status of EU GMP certification and international growth outlook? - Management expects to complete the EU GMP certification by summer and anticipates material growth in international business, albeit from a small base [39] Question: What is the current status of the U.S. assets, particularly Parallel and Skymint? - Management noted that they are nearing resolution on the foreclosure process for Parallel and expect to finalize it in Q2 [50]

Financial Data and Key Metrics Changes - The company reported consolidated net revenue of approximately $97.8 million for Q4 2025, a decrease of 16.5% year-over-year [9] - Adjusted EBITDA for the fourth quarter was approximately $15.6 million, down 41.8% compared to the previous year [15] - The net loss for the quarter was approximately $54.4 million, or $12.24 per share, compared to a net loss of $35.7 million, or $7.81 per share, for Q4 2024 [21][22] Business Line Data and Key Metrics Changes - Net revenue for the radio broadcasting segment was $35.1 million, a decrease of 26.5% year-over-year, with a 10.1% decline when excluding political revenue [9] - Reach Media segment net revenue was $13.8 million, up 43.9% year-over-year, primarily due to increased event revenue from the Fantastic Voyage Cruise [11] - Digital segment net revenue decreased by 19.6% to $14.7 million, driven by lower direct revenue streams [12] - Cable television segment revenue was approximately $34.9 million, down 16.8%, with advertising revenue down 21.8% [12] Market Data and Key Metrics Changes - Local ad sales were down 19% against markets that were down 12.6%, while national ad sales decreased by 40.1% against a market decline of 29.2% [9] - The largest ad category for the quarter was services, which increased by 18.1%, primarily due to legal services [10] Company Strategy and Development Direction - The company completed a significant capital markets transaction, repurchasing a substantial amount of its 2028 notes at a discount and extending maturities to 2031 [6] - The focus remains on deleveraging the business and taking advantage of opportunities related to deregulation in the radio industry [6][7] Management's Comments on Operating Environment and Future Outlook - The first quarter of 2026 started slower than anticipated, with current radio pacings down about 5% [5] - Management expressed optimism about operational changes and upcoming political events that may positively impact performance [5] Other Important Information - The company recorded $55.3 million in non-cash impairment charges, with significant amounts attributed to the cable television segment [20] - Capital expenditures for the quarter were approximately $3.2 million, totaling $10.1 million for the year [21] Q&A Session Summary - There were no questions during the Q&A session [23]

Jazz Pharmaceuticals FY Conference Summary Company Overview - **Company**: Jazz Pharmaceuticals (NasdaqGS:JAZZ) - **Date**: March 12, 2026 - **Key Speakers**: Philip Johnson (CFO), Jack Spinks (Head of Investor Relations) Core Industry Insights Financial Performance - **2025 Revenue**: Record revenue growth of 5%, driven by: - **Xywav**: 12% growth - **Epidiolex**: 9% growth - **Modeyso**: Strong initial uptake - **Consecutive Growth**: 21st consecutive year of revenue growth [3][4] Pipeline Developments - **Zepzelca**: Positive data in first-line maintenance small cell lung cancer in combination with atezolizumab - **Zanidatamab**: Unprecedented overall survival results extending beyond 2 years in first-line GEA [3][4] - **Acquisition**: Chimerix acquisition for dordaviprone, expected to yield over $200 million in tax savings [4] 2026 Guidance - **Revenue Forecast**: $4.25 billion - $4.5 billion, aiming for 22nd consecutive year of growth [4][5] Key Product Insights Xywav and Sleep Franchise - **Performance**: Continued growth in idiopathic hypersomnia and narcolepsy markets, with Xywav showing strong patient retention and safety benefits [15][17] - **Market Dynamics**: Anticipated competition from orexin agonists, but Xywav expected to remain complementary rather than competitive [20][23] Epidiolex and Epilepsy - **Market Position**: Strong IP runway with ANDA settlements extending to late 2030s; growth opportunities in adult patient populations [24][25] - **Patient Support**: Implementation of Nurse Navigator program to improve patient experiences and treatment adherence [25][27] Oncology Portfolio - **Modeyso**: Strong uptake with potential peak sales of $500 million in the US; ongoing evaluation of patient demographics and treatment duration [29][33] - **Zepzelca**: Anticipated to become standard of care in first-line maintenance setting, with expected revenue dynamics influenced by competitive landscape [43][44] Strategic Focus Areas Corporate Development - **Investment Strategy**: Focus on existing marketed products and pipeline, with plans to expand into new rare disease areas [10][11] - **Acquisition Strategy**: Targeting post-proof of concept investments in rare diseases, leveraging existing expertise [12] Future Growth Opportunities - **Oncology Expansion**: Plans to explore additional indications for zanidatamab and potential partnerships for HER2-targeted therapies [41][42] - **Research Development**: Transitioning to a fully integrated biopharma company with ongoing phase 1 assets in NRAS and KRAS programs [46] Additional Considerations - **Market Trends**: Ongoing interest in orexin agonists and their potential impact on existing therapies; Jazz positions itself as a complementary player in the market [19][20] - **Patient-Centric Approach**: Emphasis on improving patient outcomes and experiences across all therapeutic areas, particularly in epilepsy and oncology [25][27][43] This summary encapsulates the key points from the Jazz Pharmaceuticals FY Conference, highlighting the company's financial performance, product insights, strategic focus, and future growth opportunities.

Financial Data and Key Metrics Changes - In Q4 2025, the company generated revenues of approximately $157 million, consistent with guidance, but decreased due to seasonality and budget exhaustion [10] - Adjusted EBITDA for Q4 was approximately $23 million, the highest quarterly adjusted EBITDA of the year, with an adjusted EBITDA margin of about 14% [10][11] - For the full year, corporate adjusted EBITDA loss was around $26 million, reflecting a structural rightsizing of G&A and a 12% decline in total headcount year-over-year [12] Business Line Data and Key Metrics Changes - Northeast MidCon revenue was essentially flat at $69.6 million, with an adjusted EBITDA margin expansion to 25.3% driven by gas-directed activity [11] - Dry gas revenue in the Northeast MidCon increased 5.3% quarter-over-quarter and 44% year-over-year [8][11] - Rockies revenue declined to $46.3 million, down approximately 9% sequentially, primarily due to weather and budget exhaustion [11] - Southwest revenue decreased about 10% to $50.9 million, linked to budget exhaustion and reduced oil-directed activity, but adjusted EBITDA increased to $6.8 million [11] Market Data and Key Metrics Changes - The company noted a 6% increase in rig count across the Northeast MidCon segment quarter-over-quarter [24] - The overall market is expected to be flat to slightly up in 2026, with improvements weighted towards the second half of the year [19] - Q1 2026 revenue is forecasted to be $145 million-$150 million, down approximately 3% from Q1 2025, influenced by Winter Storm Fern [20] Company Strategy and Development Direction - The company is focusing on higher margin, technically differentiated work and maintaining cost discipline while strategically deploying capital [6] - The portfolio is increasingly aligned with gas-directed opportunities, particularly in the Northeast MidCon and other gas-focused basins [19] - The capital program is predominantly maintenance-oriented, with gross capital expenditures expected to be approximately $40 million in 2026 [12][21] Management Comments on Operating Environment and Future Outlook - Management expressed a constructive but measured outlook for 2026, anticipating Q1 to be the low point of the year due to seasonal factors [18] - The company is monitoring the impact of the Middle East conflict on oil-directed activity and commodity prices, noting a historical lag in activity changes following price movements [44][48] - Management emphasized the importance of maintaining flexibility in operations and capital allocation to respond to market conditions [21][35] Other Important Information - The company ended 2025 with total debt of $258.3 million and available liquidity of approximately $56 million [13] - A proactive amendment to the indenture was made to provide covenant relief, allowing for a net leverage ratio of 4.5 times through March 31, 2027 [16] Q&A Session Summary Question: Strength in Northeast MidCon - Management noted a 6% increase in rig count and strong performance across service lines, with completion programs sustaining through year-end despite seasonal impacts [24][26] Question: Revenue Decline in Southwest - The revenue decline was attributed to budget exhaustion and completion program tailing off, with some assets being realigned to other segments [32][33] Question: CapEx and Cash Flow Outlook - The company is targeting gross capital spending of $40 million for 2026, down from $49 million, reflecting a prudent approach to spending [34][35] Question: PIK Option and Covenant Relief - Management explained the use of PIK options for flexibility in cash management and the proactive measures taken for covenant relief to cushion future periods [36][38] Question: Impact of Middle East Conflict - Management indicated that historical patterns suggest a lag in activity changes following commodity price movements, with operators currently taking a wait-and-see approach [44][48]

Financial Data and Key Metrics Changes - In Q4 2025, the company generated net revenues of $6.6 million and EBITDA of $1.5 million, reflecting a decline compared to the same period last year due to a reduction in fleet and softer market conditions [3][12] - For the full year 2025, net revenue totaled $37.8 million, adjusted EBITDA was $12.9 million, and the net loss reached $6.2 million [12] - Daily operating expenses were successfully reduced to approximately $6,300 per day [13] Business Line Data and Key Metrics Changes - The company executed strategic initiatives to enhance earnings, including divesting lower-returning assets and redeploying proceeds into higher-earning Capesize exposure [4] - The fleet utilization remained high at 97.6%, and the fourth quarter TCE was $14,129, consistent with the same period in 2024 [6] Market Data and Key Metrics Changes - The Baltic Kamsarmax Index averaged about $14,800 in early 2026, up from $9,600 during the same period in 2025, while the Baltic Capesize Index averaged about $23,000, compared to $13,000 last year [8] - The Panamax market showed strong growth in grain and minor bulk ton-miles, while coal trade has moderated [9] Company Strategy and Development Direction - The company is focused on disciplined capital reallocation, divesting lower-returning assets, and enhancing cash flow visibility through fixed-rate charters [4][5] - The addition of two Capesize vessels is expected to produce meaningful returns on capital and enhance earnings visibility through the end of 2026 [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining competitive distributions while pursuing growth opportunities, despite the geopolitical crisis affecting the global outlook [4][9] - The company anticipates a daily time charter equivalent of approximately $15,230 for Q1 2026, with 92% of available days already fixed [7] Other Important Information - The company declared its thirteenth consecutive quarterly dividend, reflecting a commitment to capital returns, with cumulative cash dividends of approximately $1.84 per share since the program's initiation [3] - The cash position at year-end stood at $14.6 million, with expectations for liquidity normalization following recent transactions [13][14] Q&A Session Summary Question: Dividend policy and future payouts - Management intends to establish a clear formula for dividends, emphasizing a commitment to generous shareholder returns [21][22] Question: Acquisition details of the Squireship - The fixed rate for the Squireship is approximately $28,000, with a strategy to finance the acquisition through leverage [23] Question: Implications of coal trade flows due to geopolitical issues - Management expects increased coal trade as a response to disruptions in LNG supply, particularly in regions reliant on Persian Gulf natural gas [24][25] Question: Fleet presence in the Gulf area - Management noted that about 2% of the global fleet is in the Gulf area, which could impact market dynamics [26]

Commission (the "SEC"), as part of Algoma's Annual Report on Form 40 - F (available at www.sec.gov), as well as in Algoma's current reports with the Canadian securities regulatory authorities and the SEC. Given these risks, uncertainties and other factors, readers should not place undue reliance on forward ‐looking statements or information as a prediction of actual results. The forward ‐looking statements and information reflects management's current expectations and beliefs regarding future events and ope ...